Sign in or Register   Sign in or Register
  |  

Mouse Anti-NUTM1 Recombinant Antibody (1G6) (CBMAB-N0571-WJ)

This product is a Mouse antibody that recognizes NUTM1. The antibody 1G6 can be used for immunoassay techniques such as: WB, IHC, IF, IHC-P.
See all NUTM1 antibodies

Summary

Host Animal
Mouse
Specificity
Human, Mouse
Clone
1G6
Antibody Isotype
IgG1, κ
Application
WB, IHC, IF, IHC-P

Basic Information

Specificity
Human, Mouse
Antibody Isotype
IgG1, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Concentration
1.0 mg/mL
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
NUT Midline Carcinoma Family Member 1
Introduction
NUTM1 (NUT Midline Carcinoma Family Member 1) is a Protein Coding gene. Diseases associated with NUTM1 include Nut Midline Carcinoma and Extragonadal Nonseminomatous Germ Cell Tumor. Among its related pathways are Chromatin Regulation / Acetylation. An important paralog of this gene is NUTM2G.
Entrez Gene ID
Human256646
Mouse213765
UniProt ID
HumanQ86Y26
MouseQ8BHP2
Alternative Names
NUT Midline Carcinoma Family Member 1; Nuclear Protein In Testis; C15orf55; NUT; Chromosome 15 Open Reading Frame 55; NUT Family Member 1; FAM22H;
Function
Plays a role in the regulation of proliferation. Regulates TERT expression by modulating SP1 binding to TERT promoter binding sites.
Cellular Location
Cytoplasm
Nucleus
Shuttles between nucleus and cytoplasm.
Involvement in disease
A chromosomal aberration involving NUTM1 is found in a rare, aggressive, and lethal carcinoma arising in midline organs of young people. Translocation t(15;19)(q14;p13) with BRD4 which produces a BRD4-NUTM1 fusion protein.
A chromosomal aberration involving NUTM1 is found in a rare, aggressive, and lethal carcinoma arising in midline organs of young people. Translocation t(15;9)(q14;q34) with BRD3 which produces a BRD3-NUTM1 fusion protein.
PTM
Methylated at Gln-1046 by N6AMT1.
Phosphorylation on Ser-1026, Ser-1029 or Ser-1031 is important for cytoplasmic export.

Cheng, M. L., Huang, Y., Luong, N., LoPiccolo, J., Nishino, M., Sholl, L. M., ... & French, C. A. (2023). Exceptional response to bromodomain and extraterminal domain inhibitor therapy with BMS-986158 in BRD4-NUTM1 NUT carcinoma harboring a BRD4 splice site mutation. JCO Precision Oncology, 7, e2200633.

Van Treeck, B. J., Thangaiah, J. J., Torres-Mora, J., Stevens, T. M., Rothermundt, C., Fassan, M., ... & Folpe, A. L. (2021). NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis. Modern Pathology, 34(8), 1547-1557.

Boer, J. M., Valsecchi, M. G., Hormann, F. M., Antić, Ž., Zaliova, M., Schwab, C., ... & Pieters, R. (2021). Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study. Leukemia, 35(10), 2978-2982.

Luo, W., Stevens, T. M., Stafford, P., Miettinen, M., Gatalica, Z., & Vranic, S. (2021). NUTM1-rearranged neoplasms—a heterogeneous group of primitive tumors with expanding spectrum of histology and molecular alterations—an updated review. Current Oncology, 28(6), 4485-4503.

Parra, O., Kerr, D. A., Bridge, J. A., Loehrer, A. P., & Linos, K. (2021). A case of YAP1 and NUTM1 rearranged porocarcinoma with corresponding immunohistochemical expression: review of recent advances in poroma and porocarcinoma pathogenesis with potential diagnostic utility. Journal of cutaneous pathology, 48(1), 95-101.

McEvoy, C. R., Fox, S. B., & Prall, O. W. (2020). Emerging entities in NUTM1‐rearranged neoplasms. Genes, Chromosomes and Cancer, 59(6), 375-385.

Chien, Y. W., Hsieh, T. H., Chu, P. Y., Hsieh, S. M., Liu, M. L., Lee, J. C., ... & Kao, Y. C. (2019). Primary malignant epithelioid and rhabdoid tumor of bone harboring ZNF532‐NUTM1 fusion: the expanding NUT cancer family. Genes, Chromosomes and Cancer, 58(11), 809-814.

Stevens, T. M., Morlote, D., Xiu, J., Swensen, J., Brandwein-Weber, M., Miettinen, M. M., ... & Bridge, J. A. (2019). NUTM1-rearranged neoplasia: a multi-institution experience yields novel fusion partners and expands the histologic spectrum. Modern Pathology, 32(6), 764-773.

Le Loarer, F., Pissaloux, D., Watson, S., Godfraind, C., Galmiche-Rolland, L., Silva, K., ... & Tirode, F. (2019). Clinicopathologic features of CIC-NUTM1 sarcomas, a new molecular variant of the family of CIC-fused sarcomas. The American journal of surgical pathology, 43(2), 268-276.

Sekine, S., Kiyono, T., Ryo, E., Ogawa, R., Wakai, S., Ichikawa, H., ... & Mori, T. (2019). Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. The Journal of clinical investigation, 129(9), 3827-3832.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-NUTM1 Recombinant Antibody (1G6)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare